This site is for customers in Japan. Customers in other regions, please go to Global page.
HOME > Product search results > Code No. CY-8079 CircuLex Human PCSK9 ELISA Kit

Code No. CY-8079

CircuLex Human PCSK9 ELISA Kit

Price

¥98,000

Availability (in Japan)

1-9

(In Japan at 00:05,
Nov 22, 2018 in JST)

Size

96 assays

Data

Components Microplate, Wash Buffer, Dilution Buffer, PCSK9 Standard, HRP conjugated Detection Antibody, Substrate Reagent, Stop Solution
Intended use This Kit is used for the quantitative measurement of Human PCSK9 in serum, plasma, cell culture medium and other biological media.
Storage temp. 4°C Manufacturer MBL
Animal species
[Gene ID]
Human
Sample Serum, Plasma, Cell culture medium, Other biological media
Measurement range 0.16~10 ng/mL
Sensitivity 0.154 ng/mL~
Related products CY-8078 CircuLex Mouse/Rat PCSK9 ELISA Kit
CY-8151 CircuLex AGE-RAGE in vitro Binding Assay Kit
CY-M1032 Anti-PCSK9 prodomain (Human) mAb
CY-M1033 Anti-PCSK9 (Human) mAb
CY-R2310 PCSK9 Wild Type in culture medium
CY-R2320 PCSK9 Wild Type/Δ53 in culture medium
CY-R2311 PCSK9 D374Y in culture medium
CY-R2321 CircuLex PCSK9 D374Y/Δ53 in culture medium
CY-R2330 PCSK9 Wild Type (Human)
CY-R2331 PCSK9 D374Y
CY-R2333 PCSK9 R194A
CY-8150 CircuLex PCSK9-LDLR in vitro Binding Assay Kit
CY-8152 CircuLex PCSK9-cIAP1 in vitro Binding Assay Kit
CY-R2340 LDLR EGF-AB domain
CY-R2341 LDLR EGF-AB domain, Myc-tagged
CY-R2342 LDLR EGF-AB domain H306Y
CY-R2343 LDLR EGF-AB domain H306Y, Myc-tagged
CY-8112 CircuLex Human STAP1 ELISA Kit
CY-8153 CircuLex Human PCSK9 Functional Assay Kit
Citations
  1. Noguchi T et al. The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis 210, 166-172 (2010)(PMID:20006333)
  1. Cariou B et al. Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. Atherosclerosis 211, 700-702 (2010)(PMID:20452593)
  1. Costet P et al. Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non additive fashion in diabetic patients. Atherosclerosis 212, 246-251 (2010)(PMID:20619837)
  1. Noguchi T et al. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study. Atherosclerosis 217, 165-70 (2011)(PMID:21411093)
  1. Mayne J et al. Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture. Clin Chem. 57,1415 (2011)(PMID:21813713)
  1. Vergès B et al. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes. Atherosclerosis. 219, 342-8 (2011)(PMID:21889145)
  1. Lena Persson. Studies on PCSK9 in the regulation of cholesterol metabolism. Published by Karolinska Institutet. Stockholm 2011
  1. Cariou B et al. Clinical aspects of PCSK9. Atherosclerosis. 216, 258-65 (2011)(PMID:21596380)
  1. Persson L et al. Endogenous Estrogens Lower Plasma PCSK9 and LDL Cholesterol But Not Lp(a) or Bile Acid Synthesis in Women. Arterioscler Thromb Vasc Biol. 32, 810-4 (2011)(PMID:22207727)
  1. Kawashiri MA et al. Efficacy and Safety of Coadministration of Rosuvastatin, Ezetimibe, and Colestimide in Heterozygous Familial Hypercholesterolemia. Am J Cardiol. 109, 364-9 (2011)(PMID:22112743)
  1. Lindholm MW et al. PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates. Mol Ther. 20, 376-81 (2012)(PMID:22108858)
  1. Cameron J et al. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor_independent pathways. Translational Research. 160, 125-30 (2012)(PMID:22683370)
  1. Huijgen R et al. Plasma levels of proprotein convertase subtilisin Kexin type 9 (PCSK9) and phenotypic variability in familial hypercholesterolemia. J Lipid Res. 53, 979-83 (2012)(PMID:22375030)
  1. Cariou B et al. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr Metab. 10, 4 (2013)(PMID:23298392)
  1. Lee CJ et al. Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects. Metabolism. 62, 845-50 (2013)(PMID:23380568)
  1. Le Bras M et al. Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. J Clin Endocrinol Metab. 98, E732-6 (2013)(PMID:23450051)
  1. Mayne J et al. Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations. Lipids Health Dis. 12, 70 (2013)(PMID:23663650)
  1. Peticca P et al. Human Serum PCSK9 Is Elevated at Parturition in Comparison to Nonpregnant Subjects While Serum PCSK9 from Umbilical Cord Blood is Lower Compared to Maternal Blood. ISRN Endocrinol. 2013, 341632 (2013)(PMID:23862071)
  1. Tremblay AJ et al. Short-term, high-fat diet increases the expression of key intestinal genes involved in lipoprotein metabolism in healthy men. Am J Clin Nutr. 98, 32-41 (2013)(PMID:23719552)
  1. Conway V et al. Impact of buttermilk consumption on plasma lipids and surrogate markers of cholesterol homeostasis in men and women. Nutr Metab Cardiovasc Dis. 23, 1255-62 (2013)(PMID:23786821)
  1. Lambert G et al. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects. J Am Coll Cardiol. 63, 2365-73 (2014)(PMID:24632287)
  1. Werner C et al. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vascul Pharmacol. 62, 94-102 (2014)(PMID:24685817)
  1. Abujrad H et al. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels. Atherosclerosis. 233, 123-9 (2014)(PMID:24529132)
  1. Jia YJ et al. Short- and long-term effects of Xuezhikang (), an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels. Chin J Integr Med. (2014)(PMID:24993334)
  1. Bonde Y et al. Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. J Lipid Res. 55, 2408-15 (2014)(PMID:25172631)
  1. Mbikay M et al. Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture. FEBS Open Bio. 4, 755-62 (2014)(PMID:25349780)
  1. Iggman D et al. Role of dietary fats in modulating cardiometabolic risk during moderate weight gain: a randomized double-blind overfeeding trial (LIPOGAIN study). J Am Heart Assoc. 3, e001095 (2014)(PMID:25319187)
  1. Xu RX et al. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease. Lipids Health Dis. 13, 188 (2014)(PMID:25496400)
  1. Ghosh M et al. Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol. J Lipid Res. 56, 463-9 (2015)(PMID:25535288)
  1. Xu RX et al. Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms. J Transl Med. 13, 87 (2015)(PMID:25889684)
  1. Starr AE et al. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells. FEBS J. 282, 2682-96 (2015)(PMID:25913303)
  1. Rosqvist F et al. Potential role of milk fat globule membrane in modulating plasma lipoproteins, gene expression, and cholesterol metabolism in humans: a randomized study. Am J Clin Nutr. 102, 20-30 (2015)(PMID:26016870)
  1. Butkinaree C et al. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. J Biol Chem. 290, 18609-20 (2015)(PMID:26085104)
  1. van Pelgeest EP et al. Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial. Br J Clin Pharmacol. 80, 1350-61 (2015)(PMID:26261033)
  1. Wassef H et al. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans. J Clin Lipidol. 9, 664-75 (2015)(PMID:26350813)
  1. Si-Tayeb K et al. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia. Dis Model Mech. 9, 81-90 (2016)(PMID:26586530)
  1. Rogacev KS et al. PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR. PLoS One 11, e0146920 (2016)(PMID:26799206)
  1. Miasan A et al. Effects of LDL Receptor Modulation on Lymphatic Function. Sci Rep. 6, 27862 (2016)(PMID:27279328)
  1. Vlachopopulos C et al. Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis. Atherosclerosis. 252, 50-60 (2016)(PMID:27501130)
  1. Li S et al. Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C. Oncotarget 8, 12333-12341 (2017)(PMID:27713142)
  1. Navarese EP et al. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study. Int J Cardiol. 227, 644-649 (2017)(PMID:27810295)
  1. Suzuki Y et al. Biodegradable lipid nanoparticles induce a prolonged RNA interference-mediated protein knockdown and show rapid hepatic clearance in mice and nonhuman primates. Int J Pharm. 519, 34-43 (2017)(PMID:28089936)
  1. Li S et al. Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity. Sci Rep. 7, 360 (2017)(PMID:28336922)
  1. Hyrina A et al. Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9. EBioMedicine. 23, 68-78 (2017)(PMID:28864162)
  1. Blanchard C et al. Roux-en-Y gastric bypass reduces plasma cholesterol in diet-induced obese mice by affecting trans-intestinal cholesterol excretion and intestinal cholesterol absorption. Int J Obes. (2017) In press.(PMID:29135972)
Product category
Research area
Metabolism
Drug discovery
この製品に関するお問い合わせをする

  • The availability is based on the information in Japan at 00:05, Nov 22, 2018 in JST.
  • The special price is shown in red color.
  • Please note that products cannot be ordered from this website. To purchase the items listed in this website, please contact us or local distributers.
  • For storage temparature: RT: room temparature
  • Please note that products in this website might be changed or discontinued without notification in advance for quality improvement.